Some of the most important technological developments in
biotechnology in recent years are summarized under the term
„Next Generation Sequencing (NGS)“. While the deciphering of the first
human genome (3 gigabases per haploid genome) took about 15 years and
roughly 300 millions of US dollars in material costs only, today the
raw sequencing data for a complete human genome (100 gigabases at 30x
coverage) can be produced by a single machine within a few days and for
just 10,000 US dollars.
This technological quantum leap has paved
the way for numerous exciting applications: apart from de
novo-sequencing, the new technologies are leveraged for transcriptome
analysis (RNA-seq), methylome analysis (methyl-seq), the determination
of transcription factor binding sites (ChIP-seq), the detection of
disease-causing mutations, and the exploration of largely unknown
ecosystems (metagenomics).
ATLAS Biolabs offers next-gen sequencing
services on all major platforms in the field (Roche/454;
Illumina/Solexa; Life Technologies/SOLiD), as well as the analysis of
NGS data. In addition, we can provide our customers with combined
solutions for targeted sequence enrichment and next generation
sequencing, which in many cases is superior to whole-genome NGS.
Especially, we are offering several possibilities for exome enrichment
and sequencing.
